Nonmyeloablative Allogeneic Stem-Cell Transplantation for Hematologic Malignancies: A Systematic Review

Benjamin Djulbegovic, MD, PhD, Jerome Seidenfeld, PhD, Claudia Bonnell, BSN, MLS, Ambuj Kumar, MD, MPH

Cancer Control. 2003;10(1) 

In This Article

Evidence by Disease

Table 4 summarizes available data from the 25 selected publications according to malignancy. Note that this table aggregates and pools data from multiple references of considerable heterogeneity concerning differences in patient selection criteria, conditioning regimens, timing of NM-allo-SCT (after auto-SCT, in first or second remission, or after relapse), and comorbid conditions (age and exclusion criteria due to other organ dysfunction). Therefore, these data should be interpreted with caution.

No published reports have compared the effects of NM-allo-SCT with those of standard allo-SCT, either respectively or prospectively, in patients eligible for standard allo-SCT. Likewise, data are lacking to compare outcomes of NM-allo-SCT with those of standard treatment. Thus, definitive conclusions are not possible regarding net health outcomes in patients ineligible for standard allo-SCT. Overall, the available evidence on effects of NM-allo-SCT in specific hematologic malignancies is limited and of poor quality.

Firm recommendations regarding the net benefits of NM-allo-SCT in the management of hematologic malignancies are precluded by the lack of comparative data, the extreme heterogeneity of the studies, the short follow-up, and the relatively small number of patients studied to date. Initiation of disease-specific studies with clearly defined eligibility criteria are needed to further elucidate the safety and efficacy of NM-allo-SCT.

The print version of this article was originally certified for CME credit. For accreditation details, contact the publisher. H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL 33612. Telephone: (813) 632-1349. Fax: (813) 903-4950. Email: ccjournal@moffitt.usf.edu.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....